ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 262 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 1.06 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,068,796 | +262.0% | 291,209 | +316.0% | 0.00% | – |
| Q2 2023 | $1,676,524 | -49.0% | 70,001 | -59.9% | 0.00% | – |
| Q1 2023 | $3,287,534 | -48.0% | 174,683 | -56.0% | 0.00% | -100.0% |
| Q4 2022 | $6,316,387 | -38.5% | 396,758 | -36.8% | 0.00% | -66.7% |
| Q3 2022 | $10,263,000 | -31.9% | 627,379 | -41.3% | 0.00% | -25.0% |
| Q2 2022 | $15,061,000 | +0.7% | 1,068,897 | +73.1% | 0.00% | +33.3% |
| Q1 2022 | $14,956,000 | +1.2% | 617,538 | -2.5% | 0.00% | 0.0% |
| Q4 2021 | $14,778,000 | -23.4% | 633,175 | -45.5% | 0.00% | -40.0% |
| Q3 2021 | $19,291,000 | +43.7% | 1,161,491 | +111.1% | 0.01% | +66.7% |
| Q2 2021 | $13,422,000 | -39.2% | 550,306 | -35.6% | 0.00% | -25.0% |
| Q1 2021 | $22,062,000 | -72.3% | 855,154 | -42.7% | 0.00% | -81.0% |
| Q4 2020 | $79,721,000 | -31.3% | 1,491,229 | -47.0% | 0.02% | -36.4% |
| Q3 2020 | $116,023,000 | -42.1% | 2,812,651 | -32.0% | 0.03% | -54.2% |
| Q2 2020 | $200,515,000 | +21.4% | 4,136,883 | +5.8% | 0.07% | -2.7% |
| Q1 2020 | $165,212,000 | +16.5% | 3,910,355 | +17.9% | 0.07% | +19.4% |
| Q4 2019 | $141,828,000 | +60.3% | 3,315,297 | +34.8% | 0.06% | +51.2% |
| Q3 2019 | $88,502,000 | +66.2% | 2,459,091 | +23.4% | 0.04% | +70.8% |
| Q2 2019 | $53,263,000 | +3.6% | 1,992,654 | +4.1% | 0.02% | -7.7% |
| Q1 2019 | $51,402,000 | +1.1% | 1,914,440 | -39.1% | 0.03% | -7.1% |
| Q4 2018 | $50,835,000 | -15.2% | 3,143,822 | +8.8% | 0.03% | +3.7% |
| Q3 2018 | $59,960,000 | +1248.9% | 2,888,220 | +892.4% | 0.03% | +800.0% |
| Q2 2018 | $4,445,000 | +7.6% | 291,038 | +58.3% | 0.00% | 0.0% |
| Q1 2018 | $4,132,000 | -34.4% | 183,880 | -12.1% | 0.00% | 0.0% |
| Q4 2017 | $6,296,000 | -9.3% | 209,092 | +13.4% | 0.00% | -40.0% |
| Q3 2017 | $6,943,000 | +92.3% | 184,312 | +42.3% | 0.01% | +66.7% |
| Q2 2017 | $3,611,000 | -33.4% | 129,492 | -17.9% | 0.00% | -40.0% |
| Q1 2017 | $5,424,000 | -76.0% | 157,780 | -79.8% | 0.01% | -78.3% |
| Q4 2016 | $22,554,000 | +263.0% | 782,052 | +300.3% | 0.02% | +228.6% |
| Q3 2016 | $6,214,000 | +272.1% | 195,372 | +227.2% | 0.01% | +250.0% |
| Q1 2016 | $1,670,000 | -95.9% | 59,717 | -94.7% | 0.00% | -95.5% |
| Q4 2015 | $40,246,000 | -1.9% | 1,128,935 | -9.0% | 0.04% | +12.8% |
| Q3 2015 | $41,010,000 | +620.9% | 1,240,119 | +813.0% | 0.04% | +680.0% |
| Q2 2015 | $5,689,000 | -17.6% | 135,832 | -35.9% | 0.01% | -28.6% |
| Q1 2015 | $6,908,000 | -75.7% | 211,952 | -76.4% | 0.01% | -75.0% |
| Q4 2014 | $28,465,000 | +77.5% | 896,555 | +38.4% | 0.03% | +64.7% |
| Q3 2014 | $16,037,000 | +98.8% | 647,694 | +81.4% | 0.02% | +88.9% |
| Q2 2014 | $8,067,000 | +734.2% | 357,120 | +798.3% | 0.01% | +800.0% |
| Q1 2014 | $967,000 | +306.3% | 39,756 | +318.0% | 0.00% | – |
| Q4 2013 | $238,000 | -63.4% | 9,510 | -59.8% | 0.00% | -100.0% |
| Q3 2013 | $651,000 | -52.3% | 23,686 | -68.5% | 0.00% | -50.0% |
| Q2 2013 | $1,366,000 | – | 75,259 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |